menu Home

Program

  • DAY 1 / Aug. 30(Fri), 2024
  • DAY 2 / Aug. 31(Sat), 2024

DAY 1 / Aug. 30(Fri), 2024

Moderator: Jongwook PARK (Korea)

Time Program Chair / Speaker
10:30-11:30 Poster Session
11:30-12:30 Lunch
12:30-12:50 Welcome Remarks Sung Kyu HONG (President, KPS)
Ji Youl LEE (President, APSU)
Jun Hyuk HONG (President, KUA)
12:50-14:00 Session I: Urothelial Cancer I (NMIBC) Jun Sung KOH (Korea)
Masatoshi ETO (Japan)
12:50-13:05 Management of recurrent low-grade intermediate-risk bladder cancer despite intravesical chemotherapy or BCG Se Young CHOI (Korea)
13:05-13:20 Is re-TURB really necessary for all high-grade NMIBC? Sungchan PARK (Korea)
13:20-13:50 Emerging therapies in non-muscle invasive bladder cancer Seth LERNER (USA)
13:50-14:00 Case Discussion:
Low grade, recurrent, intermediate-risk NMIBC refractory to BCG
Moderator:
Taek Sang KIM (Korea)
Kyung Jin JUNG (Korea)
Kwang Hyun KIM (Korea)
Lukman HAKIM (Indonesia)
14:00-14:20 Satellite Symposium sponsored by Janssen Sung Kyu HONG (Korea)
The role of Erleada in mHSPC: optimal start, saving other options for the future Phil Hyun SONG (Korea)
14:20-14:40 Coffee Break / Visit Exhibits
14:40-16:40 Session II: Prostate Cancer I Jae Il CHUNG (Korea)
Jae Young JOUNG (Korea)
14:40-15:10 The evolution of radical prostatectomy in the management of prostate cancer James EASTHAM (USA)
15:10-15:20 Q & A
15:20-15:50 Sequencing systemic therapies post ARPI in mHRPC Deaglan McHugh (USA)
15:50-16:00 Q & A
16:00-16:30 Highlights of APCCC 2024 Silke GILLESSEN (Switzerland)
16:30-16:40 Q & A
Panels discussion Gyeong Eun MIN (Korea)
Won Tae KIM (Korea)
Ki Soo LEE (Korea)
Jongsoo LEE (Korea)
17:00 Welcome Dinner

DAY 2 / Aug. 31(Sat), 2024

Moderator: Jongwook PARK (Korea)

Time Program Chair / Speaker
09:00-10:10 Session III: Prostate Cancer II (Locally advanced disease) Ji Youl LEE (Korea)
Hung-Jen Wang (Taiwan)
09:00-09:15 How to best manage patients with locally advanced prostate cancer?;
Surgery vs Radiation therapy
Hongzoo PARK (Korea)
09:15-09:30 How to best manage patients with locally advanced prostate cancer?;
Adjuvant vs Early salvage Radiation therapy
Hakmin LEE (Korea)
09:30-10:00 Is it all or is it none? Role of pelvic lymph node dissection at the time of radical prostatectomy James EASTHAM (USA)
10:00-10:10 Case Discussion:
Locally advanced prostate cancer
Moderator:
Hyung Joon KIM (Korea)
Jae Duck CHOI (Korea)
Yu Seob SHIN (Korea)
Sang Hun SONG (Korea)
10:10-10:30 Commemorative Photo & Coffee Break / Visit Exhibits
10:30-11:40 Session IV: Urothelial Cancer II (Advanced disease) Tag Keun YOO (Korea)
Moon Ki JO (Korea)
10:30-10:45 Are genetic testings helpful for treatment decision making in patients with MIBC? Byeong do SONG (Korea)
10:45-11:00 Immuno-oncological agents for metastatic urothelial carcinoma: status quo Jong Wook KIM (Korea)
11:00-11:30 Evidence for the anatomic extent of lymphadenectomy with radical cystectomy Seth LERNER (USA)
11:30-11:40 Case Discussion:
Management of complete clinical response following neoadjuvant systemic therapy for MIBC
Moderator:
Jong Kil NAM (Korea)
Wansuk KIM (Korea)
Yun Beom KIM (Korea)
Hung-Jen Wang (Taiwan)
11:40-12:40 Luncheon Symposium sponsored by Astellas Sung Kyu HONG (Korea)
11:40-12:00 The Role of Harnal D as an Initial Treatment for LUTS/BPH Hee Jo YANG (Korea)
12:00-12:40 Lunch
12:40-13:50 Session V: Prostate Cancer III (Management of BCR) Kyung Seop LEE (Korea)
Lukman HAKIM (Indonesia)
12:40-12:55 How do we identify patients with BCR who are eligible to delay salvage treatment? Byung Hoon KIM (Korea)
12:55-13:10 Difficulties in the interpretations of PSMA PET imaging Yoo Sung SONG (Korea)
13:10-13:25 Can ARPi treatment bring changes in the management of BCR? Dongho SHIN (Korea)
13:25-13:40 Optimal strategy for BCR after radical prostatectomy Yong Hyun PARK (Korea)
13:40-13:50 Case Discussion:
High-risk BCR after radical prostatectomy. What to do?
Moderator:
Kyo Chul Koo (Korea)
Hyun Chul CHUNG (Korea)
Jae Seung CHUNG (Korea)
Jin Sung PARK (Korea)
Gyoohwan JUNG (Korea)
13:50-14:10 Satellite Symposium sponsored by Novartis Sung Kyu HONG (Korea)
Current insights on Lutetium-177-PSMA-617 radioligand therapy (PLUVICTO) for metastatic castration-resistant prostate cancer Jae Young JOUNG (Korea)
14:10-14:30 Coffee Break / Visit Exhibits
14:30-15:40 Session VI: Prostate Cancer IV (mCSPC) Jun Hyuk HONG (Korea)
Taek Won KANG (Korea)
14:30-14:45 Sequencing of therapies following treatment intensification for mCSPC See Min CHOI (Korea)
14:45-15:00 Updates on metastasis directed therapy (MDT) for oligometastatic disease Bum Sik TAE (Korea)
15:00-15:30 Personalizing therapy in mHSPC Deaglan McHugh (USA)
15:30-15:40 Case discussion:
mCSPC
Moderator:
Seong Hyeon YU (Korea)
Tae Hyo KIM (Korea)
Seyun KWON (Korea)
Jeong Woo LEE (Korea)
15:40-15:50 Best Abstract Prize
15:50-15:55 Closing Remarks Sung Kyu HONG (President, KPS)
17:00 Banquet
go to top

Copyright(C) by 2024 KPS in conjunction with APSU Joint International Symposium.
All rights reserved.

Secretariat of KPS

Gaon Convention Services, Inc.
ADDRESS: Room 1005, 228, Gonghang-daero, Gangseo-gu, Seoul, Republic of Korea.
TEL : +82-2-6956-7989   |   E-MAIL : gaonpco@gaonpco.com

close

사전등록

등록구분
근무처
소속의사회

* 의사 회원인 경우에는 연수평점 카드 기록을 위해서 필요 합니다.